Mereo BioPharma Group plc PDMR Notification (5661O)
02 Outubro 2019 - 11:54AM
UK Regulatory
TIDMMPH
RNS Number : 5661O
Mereo BioPharma Group plc
02 October 2019
Mereo BioPharma Group plc
("Mereo" or the "Company")
Notification of PDMR Dealing
London, October 02, 2019 - Mereo BioPharma Group plc (AIM: MPH,
NASDAQ: MREO), a clinical stage UK based biopharmaceutical company
focused on rare diseases, received notification that on September
30, 2019, John Richard, Head of Corporate Development, purchased
1500 American Depositary Shares (ADSs) at a price of USD2.96 per
ADS.
The below announcement and notification is made in accordance
with the EU Market Abuse Regulation. The form required under the EU
Market Abuse Regulation follows.
1 Details of the person discharging managerial responsibilities
a) Name John Richard
------------------------ --------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------
a) Position/status Head of Corporate Development
------------------------ --------------------------------------------------
b) Initial notification/ Initial notification
Amendment
------------------------ --------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------
a) Name Mereo BioPharma Group plc
------------------------ --------------------------------------------------
b) LEI 213800U8JQHIJOS5AS09
------------------------ --------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------
a) Description of AMERICAN DEPOSITARY SHARE (ADS) EACH REPRESENTING
the financial 5 MEREO BIOPHARMA GROUP PLC ORDINARY SHARES
instrument, type OF GBP0.003 EACH
of instrument
and identification
code
------------------------ --------------------------------------------------
b) Nature of the PURCHASE OF ADS
transaction
------------------------ --------------------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) USD 2.96 1500
----------
------------------------ --------------------------------------------------
d) Aggregated information: Aggregated volume: 1500
volume, Price Aggregated price: USD2.958
------------------------ --------------------------------------------------
e) Date of the transaction 2019-09-30
------------------------ --------------------------------------------------
f) Place of the XNMS
transaction
------------------------ --------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHBSBDGBUGBGCD
(END) Dow Jones Newswires
October 02, 2019 10:54 ET (14:54 GMT)
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Mereo Biopharma (LSE:MPH)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
Notícias em tempo-real sobre Mereo Biopharma Group Plc da Bolsa de Valores de Londres bolsa de valores: 0 artigos recentes
Mais Notícias de Mereo Biopharma Group Plc